Challenges in using observational studies to evaluate adverse effects of treatment

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1705-1707

  Hughes, Michael D ^a   Williams, Paige L ^a  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PROTEINASE INHIBITOR;

DYSLIPIDEMIA; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY;

EID: 34247467969     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp078038     Document Type: Article

References (5)

1. Smeeth L, Douglas I, Hubbard R. Commentary: we still need observational studies of drugs - they just need to be better. Int J Epidemiol 2006;35:1310-1.
2. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven, 1998.
3. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
4. Hughes MD. Evaluating surrogate endpoints. Control Clin Trials 2002;23:703-7.
5. Phillips A, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28, 2007. abstract.